Cellular Tropism of SARS-CoV-2 across Human Tissues and Age-related Expression of ACE2 and TMPRSS2 in Immune-inflammatory Stromal CellsOpinion Published on 2021-06-012022-10-28 Journal: Aging and Disease [Category] COVID-19, [키워드] ACE2 acute respiratory syndrome alteration Analysis analyzed angiotensin-converting enzyme 2 approach Cell cell type cell types cells cellular tropism Clinical treatment coronavirus COVID-19 COVID-19 research Evidence expression Factors highlighting Human human tissue human tissues identity immune-inflammatory stromal cells indicated mechanism Older organ systems pathogen populations Research resource SARS-CoV-2 SARS-COV-2 infection scRNA-seq scRNA-seq data Single-cell RNA sequencing stromal cell TMPRSS2 TMPRSS2 expression transmembrane serine protease tropism viral entry viral pathogenesis viral tropism virus [DOI] 10.14336/AD.2021.0429 PMC 바로가기 [Article Type] Opinion
Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise ReviewReview Published on 2021-06-012022-10-29 Journal: International Journal of Medical Sciences [Category] COVID-19, [키워드] Bacterial bronchopulmonary dysplasia Cell-based therapy chronic lung disease chronic obstructive clearance clinical clinical study clinical trial community-acquired pneumonia conditions Contact COPD curative treatment death disease disorder Effect effective Efficacy ILD immunomodulatory activities Interstitial lung disease lung cancer Lung diseases mechanisms Meta-analysis morbidity MSC MSCs offer paracrine pulmonary disease pulmonary diseases pulmonary fibrosis reported Research review stromal cell syndrome systematic review Therapeutic approach therapeutic option therapeutic potential therapy tissue regeneration Treatment [DOI] 10.7150/ijms.59218 PMC 바로가기 [Article Type] Review
Human cardiosphere-derived stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expressionSARS-CoV-2에 노출된 인간 심장권 유래 기질 세포는 ACE2 수용체 발현 수준에 따라 과염증/친섬유증 표현형으로 진화하고 감염성 바이러스 입자를 생성합니다Article Published on 2021-05-252022-09-11 Journal: Cardiovascular Research [Category] SARS, 치료기술, [키워드] ACE2 ACE2 receptor analysed angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme-2 cardiac cardiac complication Cardiac complications cardiac injury Cardiac stromal cells caused Cell cellular Complication conditions COVID-19 demonstrated detect determine electron microscopy explain exposure to expression fibrosis High-resolution Human in vitro infected patients Infection infective Inflammation Injury Innate immunity involved Microscopy Myocardial Myocardium pathway PCR performed phenotype proteomics regulated reported RT-qPCR assay RT-qPCR assays SARS-CoV-2 SARS-COV-2 infection sensitivity Severe case severe cases severe respiratory syndrome stromal cell stromal cells supernatant susceptible these cell These cells transcriptomics undergo viral particle Viral particles virus [DOI] 10.1093/cvr/cvab082 PMC 바로가기 [Article Type] Article
Manufacturing freshly cultured umbilical cord-derivedmesenchymal stromal cells (UC-MSCS) for a phase 1, multiple-dose clinical trial for COVID-19-induced acute respiratory distress syndrome (ARDS)Conference abstract Published on 2021-05-012022-10-05 Journal: Cytotherapy [Category] 임상, [키워드] acute respiratory distress ARDS clinical trial Multiple-dose stromal cell syndrome umbilical [DOI] 10.1016/S146532492100342X [Article Type] Conference abstract
Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseasesReview Published on 2021-03-272022-10-27 Journal: Biotechnology and bioengineering [Category] COVID-19, MERS, [키워드] ACE2 receptor adipose Bone marrow Cell cellular clinical study cough COVID‐19 COVID‐19 infection COVID‐19 death disease Diseases example extracellular vesicle Extracellular vesicles healthy hospitalized patients IMPROVE include indicated lung Lung disease Lung diseases menstrual blood Mesenchymal stromal cell MSCs mutations outcome pandemic Particle Patient receive Respiratory Coronavirus Respiratory disease respiratory diseases Respiratory system Result secreted Secretome sick Spread stromal cell Symptom the patient therapeutic therapeutic strategy therapy tissues tolerable treat Treatment umbilical virus virus particle [DOI] 10.1002/bit.27729 PMC 바로가기 [Article Type] Review
Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?줄기 세포와 COVID-19: 인간 양막 세포는 SARS-CoV-2 바이러스에 대한 치료법에 대한 새로운 희망입니까?Review Published on 2021-03-012022-09-10 Journal: Stem Cell Research & Therapy [Category] 임상, [키워드] Amnion amniotic anti-inflammatory properties applied caused Cell Cell therapy clinical trial clinical trials coronavirus COVID-19 COVID-19 treatment cytokine Diseases effective epithelial cell epithelial cells hAEC Health Human amniotic epithelial cells Human amniotic mesenchymal stromal cells in some in vivo models Inflammatory response Lung disease Lung diseases Lung infection Lung injury membrane Mesenchymal stem cells MSC MSCs New coronavirus pandemic Patient patients with COVID-19 Placenta positioned preclinical studies preclinical study problems producing Proinflammatory cytokine reduced regenerative respiratory Respiratory disease respiratory diseases restored Safe SARS-CoV-2 SARS-CoV-2 virus severe patients stem cell Stem cell therapy stem cells stromal cell stromal cells suggested term tested the SARS-CoV-2 the SARS-CoV-2 virus therapy therapy for COVID-19 tissue Treatment Trigger triggers [DOI] 10.1186/s13287-021-02216-w PMC 바로가기 [Article Type] Review
Challenges and advances in clinical applications of mesenchymal stromal cells간엽 기질 세포의 임상 응용 분야에서의 도전과 발전Review Published on 2021-02-122022-09-10 Journal: Journal of Hematology & Oncology [Category] Fulltext, MERS, 비임상, [키워드] approach Artificial intelligence (AI) breath challenge Clinical applications clinical trial COVID-19 COVID-19 pandemic criteria disease disease models Diversity Extracellular vesicles Factor heterogeneity highest human disease human diseases identity improvement investigated majority Mesenchymal stem cells Mesenchymal stromal cell Mesenchymal stromal cells modify MSC MSC therapy MSCs outcome overcome pandemic disease Registered stem cells stromal cell stromal cells therapeutic potential [DOI] 10.1186/s13045-021-01037-x PMC 바로가기 [Article Type] Review
Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial중증 및 중환자 COVID-19 환자 치료에서 인간 월경혈유래 중간엽 기질 세포의 안전성 및 효능 평가: 탐색적 임상 시험Clinical Trial Published on 2021-01-272022-08-13 Journal: Clinical and Translational Medicine [Category] MERS, 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse event adverse events AEs Allogeneic alternative method caused chest imaging clinical trial Concomitant medication concomitant medications control group coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 (COVID‐19) COVID‐19 COVID‐19 patients Critical Critically ill died Dyspnea effective Efficacy enrolled experimental group exploratory Frequency groups incidence lack menstrual Mesenchymal stromal cell Mesenchymal stromal cells Mortality MSC MSC therapy MSCs multicenter nonrandomized not differ open‐label Patient patients problems proliferation respiratory Safety safety and efficacy SARS‐CoV‐2 secondary endpoint Secondary endpoints severe acute respiratory syndrome Coronavirus severe and critical patients significantly significantly lower Spread stromal cell stromal cells therapy treat treated Treatment Trial was measured were assessed [DOI] 10.1002/ctm2.297 PMC 바로가기 [Article Type] Clinical Trial
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS‐CoV‐2 infectionTissue‐specific Progenitor and Stem Cells Published on 2021-01-262022-10-28 Journal: Stem cells translational medicine [Category] COVID-19, MERS, SARS, [키워드] ACE2 adipose adult stem cells angiotensin Blood Bone marrow cell line cellular therapy complications conditioned COVID‐19 Critical Cytopathic effect demonstrated Effect ELISA enzyme evaluated Evidence excluded Express fetal fetal stem cells host cell host cell factor Human human tissue immunomodulatory properties medium Mesenchymal stromal cell mesenchymal stromal cells (MSCs) MSC MSCs not express potential therapy Proteins pseudovirus raised SARS‐CoV‐2 SARS‐CoV‐2 infection stromal cell Support tested therapy tissue TMPRSS2 transmembrane serine protease Treatment Viral particles virus were expressed western blot wild strain [DOI] 10.1002/sctm.20-0385 PMC 바로가기 [Article Type] Tissue‐specific Progenitor and Stem Cells
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trialCOVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-01-062022-09-10 Journal: Trials [Category] MERS, 바이오마커, 임상, 치료제, [키워드] 1:1 24 hours 7-point ordinal scale acute respiratory distress acute respiratory distress syndrome Administered administration Admission Adult patient Adult patients Adverse Adverse drug reactions AEs age All trial participants all-cause mortality allergy Allogeneic ARDS assessment assigned baseline Biomarker blinded Blinding C-reactive protein carcinoma carcinoma in situ carried cellular chain change childbearing potential Chloroquine Clinical practice clinical status clinical trial coagulation test coagulation tests conducted Control control arm Course COVID COVID-19 CRF criteria CT scan cumulative incidence current Cytokines D-dimer Day death described determined by Diagnosis disease dissemination double-blind drug Duration ECMO Efficacy Efficacy and safety element eligible End endpoints enrolment EudraCT evaluate evaluate the effect event exclusion criteria Extracorporeal extracorporeal membrane oxygenation failure ferritin fibrosis FiO2 form GRADE grade 3 greater Haemodialysis handling hemofiltration history hospital Hospitalization hydroxy ICU ICU admission IMPROVE include inclusion criteria Informed consent intravenous Intravenous administration intravenous dose intubation Invasive mechanical ventilation invasive ventilation investigational medicinal product involved laboratory confirmation laboratory-confirmed SARS-CoV-2 infection lactation LDH less Level Local Lopinavir Lopinavir/ritonavir lung disorder lymphocyte marker Mechanical mechanical ventilation Medicine Medicines Mesenchymal stromal cells moderate to severe Mortality MSC negative pregnancy test neoplasm neutrophil neutrophil counts Non-invasive number objective occur off-label opinion Ordinal Scale organ oropharyngeal swab oropharyngeal swabs Other outcome oxygen oxygen saturation Oxygen therapy PaO2 PaO2/FiO2 ratio parameters participant Patient PCR percentage Placebo polymerase chain reaction Pregnancy primary endpoint product Production profile progression protocol Pulmonary embolism pulmonary fibrosis Pulmonary function tests randomised randomised controlled trial randomization Randomized Randomly Rapid antigen tests reaction receive recruitment Registered Remdesivir report respiratory Respiratory distress syndrome Resuscitation Ritonavir SAEs Sample size SARS-COV-2 infection secondary Secondary endpoints Sequential Organ Failure Assessment Serious Adverse Events SOFA Spain specificity specimen Sponsor Standard of care status stromal cell stromal cells Study protocol subpopulations supplemental oxygen supplementary material syndrome the cell the disease the patient the primary endpoint the WHO time Tocilizumab Tolerability Treatment treatment arm treatment for COVID-19 treatment group Treatment protocol Trial trial participant Trial registration unit website women worldwide pandemic written consent [DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter